431 related articles for article (PubMed ID: 18156212)
1. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
2. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
3. Lobe-specific lineages of carcinogenesis in the transgenic adenocarcinoma of mouse prostate and their responses to chemopreventive selenium.
Wang L; Zhang J; Zhang Y; Nkhata K; Quealy E; Liao JD; Cleary MP; Lü J
Prostate; 2011 Sep; 71(13):1429-40. PubMed ID: 21360561
[TBL] [Abstract][Full Text] [Related]
4. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.
Berman-Booty LD; Thomas-Ahner JM; Bolon B; Oglesbee MJ; Clinton SK; Kulp SK; Chen CS; La Perle KM
Toxicol Pathol; 2015 Feb; 43(2):186-97. PubMed ID: 24742627
[TBL] [Abstract][Full Text] [Related]
5. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.
Gupta A; Yu X; Case T; Paul M; Shen MM; Kaestner KH; Matusik RJ
Prostate; 2013 May; 73(6):582-9. PubMed ID: 23060003
[TBL] [Abstract][Full Text] [Related]
6. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
7. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
8. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
Lab Invest; 1998 Mar; 78(3):319-33. PubMed ID: 9520945
[TBL] [Abstract][Full Text] [Related]
9. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
10. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.
Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ
Neoplasia; 2007 Nov; 9(11):938-50. PubMed ID: 18030362
[TBL] [Abstract][Full Text] [Related]
11. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
Lab Invest; 1998 Jun; 78(6):i-xv. PubMed ID: 9645768
[TBL] [Abstract][Full Text] [Related]
12. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
[TBL] [Abstract][Full Text] [Related]
13. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
14. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
[TBL] [Abstract][Full Text] [Related]
15. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
Bruckheimer EM; Brisbay S; Johnson DJ; Gingrich JR; Greenberg N; McDonnell TJ
Oncogene; 2000 Nov; 19(46):5251-8. PubMed ID: 11077442
[TBL] [Abstract][Full Text] [Related]
17. Androgen-dependent prostate epithelial cell selection by targeting ARR(2)PBneo to the LPB-Tag model of prostate cancer.
Wang Y; Kasper S; Yuan J; Jin RJ; Zhang J; Ishii K; Wills ML; Hayward SW; Matusik RJ
Lab Invest; 2006 Oct; 86(10):1074-88. PubMed ID: 16894353
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
20. Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.
Corbin JM; Overcash RF; Wren JD; Coburn A; Tipton GJ; Ezzell JA; McNaughton KK; Fung KM; Kosanke SD; Ruiz-Echevarria MJ
Prostate; 2016 Jan; 76(1):97-113. PubMed ID: 26417683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
